Investigating how proteasome overload contributes to blindness from retinitis pigmentosa
Role of Proteasome Overload in Pathogenesis of Retinitis Pigmentosa
This study is looking at how a buildup of faulty proteins in the eye affects vision in people with retinitis pigmentosa, and it aims to find ways to help the eye cells clear these proteins to help protect sight for those with this condition.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11073037 on NIH RePORTER |
What this research studies
This research focuses on retinitis pigmentosa (RP), a hereditary condition that leads to blindness, affecting millions globally. The study aims to understand how the overload of misfolded proteins in cells contributes to the degeneration of photoreceptors, which are crucial for vision. By using mouse models, researchers will explore ways to enhance the proteasome's ability to clear these proteins, potentially delaying or preventing vision loss. The ultimate goal is to identify new therapeutic strategies that could benefit a wide range of patients with different genetic mutations causing RP.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with retinitis pigmentosa, particularly those with mutations affecting proteostasis.
Not a fit: Patients with retinitis pigmentosa caused by mutations unrelated to proteostasis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or prevent blindness in patients with retinitis pigmentosa.
How similar studies have performed: Previous research has shown promise in targeting proteostasis to treat similar conditions, indicating that this approach may be viable.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Alekseev, Oleg — Duke University
- Study coordinator: Alekseev, Oleg
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.